


# Not Provided

Kelly Dempsey, MD | Sugar Land, TX, USA

	Recurrence Score <sup>®</sup> Result	Age	41	PR Status (IHC)	Not Provided
		Menopausal Status	Not Provided	HER2/NEU Status	Not Provided
		Tumor Type	Not Provided	Ki-67 Status	Not Available
		Tumor Size (cm)	Not Provided	Histologic Grade	Not Provided
		ER Status (IHC)	Not Provided	Lymph Node Status	Not Provided
		General Health	Not Provided		
		Treatment Given	Tested on core biopsy, patient had pathological complete response (PCR)		

**Disclaimer:** These case studies are brought to you for educational purposes only and should not be interpreted as an endorsement of Exact Sciences or its services by the submitting physician. The information reflects the interpretive diagnostic opinions of the treating physicians and is not intended to represent a standard of care. The case studies describe real-life cases of patients who have been prescribed the Oncotype DX<sup>®</sup> test. They are not necessarily representative of all tested patients, and the result in any given case will vary. The examples are not necessarily representative of all of those who will use our clinical tests. Exact Sciences does not endorse any of the contributors featured on this site and takes no view as to the treatment decisions reported in these cases.

Not Provided

Recurrence  
Score<sup>®</sup> Result

Not  
Provid  
ed



Lymph Node  
Status

Not  
Provided

**Exploratory Subgroup Analysis** for TAILORx and NSABP B-20 indicate that Recurrence Score<sup>®</sup> and age are the strongest predictors of chemotherapy benefit<sup>1</sup>. The absolute reduction of distant recurrence from chemotherapy for patients >50 years and ≤50 years is shown here for RS groups: 11-15, 16-20, and 21-25 from TAILORx, and 0-10 and 26-100 from NSABP B-20<sup>2</sup>.

Age	RS 0-10	RS 11-15	RS 16-20	RS 21-25	RS 26-100
>50 years	No CT Benefit (<1%)				>15% CT Benefit
≤50 years	No CT Benefit (<1%)	~1.6% CT Benefit	~6.5% CT Benefit		>15% CT Benefit

Not Provided

Recurrence  
Score<sup>®</sup> Result




Not  
Provided

Lymph Node  
Status

Not  
Provided

Estimated Chemotherapy Benefit for Individual Recurrence Score Results

Recurrence Score ranges shown reflect randomized patients in NSABP B-20 and TAILORx.



References

1. Sparano et al. N Engl J Med. 2018.; ECOG and Genomic Health (data on file).
2. Paik et al. J Clin Oncol. 2006.; Sparano and Paik J Clin Oncol. 2008.